Darlene Lu

994 total citations
22 papers, 511 citations indexed

About

Darlene Lu is a scholar working on Infectious Diseases, Molecular Biology and Virology. According to data from OpenAlex, Darlene Lu has authored 22 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 6 papers in Molecular Biology and 6 papers in Virology. Recurrent topics in Darlene Lu's work include HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (6 papers) and Bone health and osteoporosis research (5 papers). Darlene Lu is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (6 papers) and Bone health and osteoporosis research (5 papers). Darlene Lu collaborates with scholars based in United States, Switzerland and South Africa. Darlene Lu's co-authors include Susan L. Rosenkranz, Serkalem Demissie, Mary Bouxsein, Ali Guermazi, Elizabeth J. Samelson, Daniel R. Kuritzkes, Mohamed Jarraya, Douglas P. Kiel, Brett Allaire and Adriana Andrade and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Bioinformatics.

In The Last Decade

Darlene Lu

22 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Darlene Lu United States	16	180	147	100	83	77	22	511
Giancarlo Iaiani Italy	12	118 0.7×	30 0.2×	26 0.3×	112 1.3×	48 0.6×	31	359
Shiri Shulman Israel	18	122 0.7×	42 0.3×	11 0.1×	56 0.7×	61 0.8×	48	971
Margarita Silió United States	13	250 1.4×	104 0.7×	7 0.1×	36 0.4×	103 1.3×	18	513
Monica Cellini Italy	13	79 0.4×	17 0.1×	13 0.1×	23 0.3×	57 0.7×	30	480
Sivasubramanian Srinivasan Singapore	12	74 0.4×	12 0.1×	25 0.3×	138 1.7×	39 0.5×	40	400
Beth Tang United States	6	205 1.1×	88 0.6×	58 0.6×	63 0.8×	25 0.3×	7	499
Valérie Potard France	12	80 0.4×	56 0.4×	82 0.8×	158 1.9×	27 0.4×	22	357
Thomas Böhler Germany	14	109 0.6×	176 1.2×	4 0.0×	26 0.3×	180 2.3×	49	629
Piyalamporn Havanond Thailand	10	24 0.1×	45 0.3×	82 0.8×	112 1.3×	42 0.5×	23	373
Jeanette Higgins United States	13	125 0.7×	162 1.1×	5 0.1×	73 0.9×	55 0.7×	24	481

Countries citing papers authored by Darlene Lu

Since Specialization

Citations

This map shows the geographic impact of Darlene Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darlene Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darlene Lu more than expected).

Fields of papers citing papers by Darlene Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darlene Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darlene Lu. The network helps show where Darlene Lu may publish in the future.

Co-authorship network of co-authors of Darlene Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Darlene Lu. A scholar is included among the top collaborators of Darlene Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darlene Lu. Darlene Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Woo, Janghee, Darlene Lu, Andrew Lewandowski, et al.. (2023). Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Advances. 7(24). 7471–7484. 23 indexed citations

Bauer, Todd M., Armando Santoro, Chia‐Chi Lin, et al.. (2023). Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for ImmunoTherapy of Cancer. 11(11). e007353–e007353. 24 indexed citations

Lu, Darlene, Serkalem Demissie, Adam C. Gower, et al.. (2021). Temporal and Quantitative Transcriptomic Differences Define Sexual Dimorphism in Murine Postnatal Bone Aging. JBMR Plus. 6(2). e10579–e10579. 5 indexed citations

Flinn, Ian W., Ulrich Jaeger, Nirav N. Shah, et al.. (2021). A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 138(Supplement 1). 740–740. 20 indexed citations

Lu, Darlene, Julie R. Palmer, Lynn Rosenberg, et al.. (2019). Perceived racism in relation to telomere length among African American women in the Black Women's Health Study. Annals of Epidemiology. 36. 33–39. 34 indexed citations

Kaiser, Jarred, Brett Allaire, Darlene Lu, et al.. (2019). Heterogeneity and Spatial Distribution of Intravertebral Trabecular Bone Mineral Density in the Lumbar Spine Is Associated With Prevalent Vertebral Fracture. Journal of Bone and Mineral Research. 35(4). 641–648. 21 indexed citations

Kaiser, Jarred, Brett Allaire, Darlene Lu, et al.. (2018). Correspondence between bone mineral density and intervertebral disc degeneration across age and sex. Archives of Osteoporosis. 13(1). 123–123. 31 indexed citations

Allaire, Brett, Darlene Lu, Fjóla Jóhannesdóttir, et al.. (2018). Prediction of incident vertebral fracture using CT-based finite element analysis. Osteoporosis International. 30(2). 323–331. 61 indexed citations

Lu, Darlene, Yorghos Tripodis, Louis C. Gerstenfeld, & Serkalem Demissie. (2018). Clustering of temporal gene expression data with mixtures of mixed effects models with a penalized likelihood. Bioinformatics. 35(5). 778–786. 5 indexed citations

10.

Kiser, Jennifer J., Darlene Lu, Susan L. Rosenkranz, et al.. (2017). Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s. Drugs in R&D. 17(4). 557–567. 3 indexed citations

11.

Karasik, David, Serkalem Demissie, Darlene Lu, et al.. (2017). Bone Strength Estimated by Micro-Finite Element Analysis (µFEA) Is Heritable and Shares Genetic Predisposition With Areal BMD: The Framingham Study. Journal of Bone and Mineral Research. 32(11). 2151–2156. 4 indexed citations

12.

Karasik, David, Serkalem Demissie, Yanhua Zhou, et al.. (2016). Heritability and Genetic Correlations for Bone Microarchitecture: The Framingham Study Families. Journal of Bone and Mineral Research. 32(1). 106–114. 23 indexed citations

13.

Andrade, Adriana, Jérémie Guedj, Susan L. Rosenkranz, et al.. (2015). Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). AIDS. 29(18). 2419–2426. 18 indexed citations

14.

Luetkemeyer, Annie, Darlene Lu, Beatriz Grinsztejn, et al.. (2015). Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases. 60(12). 1860–1863. 21 indexed citations

15.

Gross, Robert, Lu Zheng, Alberto La Rosa, et al.. (2014). Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial. The Lancet HIV. 2(1). e12–e19. 17 indexed citations

16.

Andrade, Adriana, Susan L. Rosenkranz, Anthony R. Cillo, et al.. (2013). Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248. The Journal of Infectious Diseases. 208(6). 884–891. 47 indexed citations

17.

Luetkemeyer, Anne F., Susan L. Rosenkranz, Darlene Lu, et al.. (2013). Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clinical Infectious Diseases. 57(4). 586–593. 51 indexed citations

18.

Funderburg, Nicholas, Adriana Andrade, Ellen S. Chan, et al.. (2013). Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. PLoS ONE. 8(12). e83514–e83514. 45 indexed citations

19.

Taiwo, Babafemi, Edward P. Acosta, Patrick Ryscavage, et al.. (2013). Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 64(2). 167–173. 14 indexed citations

20.

O’Donnell, Peter H., M.S. Gordon, Kent C. Shih, et al.. (2012). 621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors. European Journal of Cancer. 48. 191–192. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact